Subscribe

National Asthma Guidelines Updated

March 2008, Vol 1, No 2 - Industry Trends
Download PDF

The National Asthma Education and Prevention Program (NAEPP) released updated clinical guidelines for the diagnosis and management of asthma on August 29, 2007.

These guidelines are the most comprehensive updates in almost a decade and include recommendations for childhood asthma (expanded section), new guidance on medications, patient education in settings beyond the physician's office, and advice for controlling environmental factors that can cause asthma symptoms.

The lifetime prevalence table above indicates an upward trend with 2006 lifetime prevalence of 116 per 1,000 persons. Additionally, the current prevalence of asthma indicates an upward trend with a 2006 current prevalence of 77.9 per 1,000 persons.

The guidelines reflect the need to assist in the diagnostic, appropriate treatments, and continued follow-up to monitor asthma patients. After long-term therapy has been initiated following spirometry assessment, the guidelines recommend continued assessment in 2 to 6 weeks based on asthma severity. If asthma control is not achieved, step-up therapy, discontinuation, and initiation of new therapy, increasing short-acting beta-agonists, and a short course of oral systemic corticosteroids are all part of the recommendations in the continued assessment for the patient.

With the prevalence of asthma attacks increasing over time (Table) and the economic impact of treating asthma patients, it will be interesting to measure adherence to the new guidelines and evaluate the clinical and economic impact of the guidelines.

Figure 1 Figure 1
Figure2
Figure2
Table
Table
Table 3
Table 3

CLINICAL

 

The tables below provide the most recent information regarding investigational drugs for asthma indication. Table 1 shows the majority (~74%) of asthma investigational drugs early in the investigational pipeline (phase 1 or earlier). Table 2 highlights the top 7 mechanisms for asthma investigational drugs, representing more than 40% of all investigational mechanisms.

 

 

Table 1. Number of Investigational Drugs
Table 1
Figure 1
Figure 1
Table 2. Top Asthma Investigational Drugs
Table 2
Figure 2
Figure 2
Related Items
Return to Business During a Pandemic: Market Collaboration and Health Benefit Trends
F. Randy Vogenberg, PhD, FASHP
June 2020 Vol 13, No 3 published on July 1, 2020 in Industry Trends
Preparing for Healthcare After COVID-19: New Challenges Facing Payers
Wayne Kuznar
June 2020 Vol 13, No 3 published on July 1, 2020 in Industry Trends
Key Trends in Healthcare for 2020 and Beyond
F. Randy Vogenberg, PhD, FASHP, John Santilli, MBA
November 2019 Vol 12, No 7 published on December 5, 2019 in Industry Trends
Value-Based Agreements in Healthcare: Willingness versus Ability
Gary Branning, MBA, Michael Lynch, CPA, MBA, Kathryn Hayes, BA
September 2019 Vol 12, No 5 published on September 17, 2019 in Industry Trends
US Healthcare Trends and Contradictions in 2019
F. Randy Vogenberg, PhD, FASHP
February 2019 Vol 12, No 1 published on February 6, 2019 in Industry Trends
Last modified: November 10, 2011
Copyright © Engage Healthcare Communications, LLC. All rights reserved.